---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013167"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:26:29.557153+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Virios acquires Pharmagesic, receives $19.5M loan, appoints new board, changes name to Dogwood Therapeutics

## Summary
- Acquired 100% of Pharmagesic from Sealbond; issued 211,383 common shares and ~2,108 Series A convertible preferred shares.
- Received $19.5M loan from CKLS affiliate; $16.5M funded at close, $3M due Feb 2025.
- Existing shareholders get CVR entitling to 87.75% of future Halneuron milestone payments over 7 years.
- Board: Richard Burch resigned; Alan Yu and Melvin Toh (CKLS) appointed; Angela Walsh promoted to CFO.
- Name change to Dogwood Therapeutics; stockholder meeting required for conversion and reverse split.

## SEC filing metadata
- accession: 0001558370-24-013167
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/viri-20241004x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013167
- JSON: https://secwatch.observer/filing/0001558370-24-013167.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013167.txt

## Key facts
- Executive change
  Angela Walsh changed role as Chief Financial Officer at Dogwood Therapeutics, Inc..
  - Action: promoted
  - Role: Chief Financial Officer
  source text: promoted Angela Walsh from her prior role of Senior Vice President of Finance to the Company’s Chief Financial Officer, effective immediately upon the Closing on October 7, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm
- Executive change
  Richard Burch resigned as Director at Dogwood Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: accepted the resignation of Richard Burch from the Board, effective as of immediately prior to the Closing on October 7, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm
- Executive change
  Melvin Toh was appointed as Director at Dogwood Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: and Melvin Toh as a director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm
- Executive change
  Alan Yu was appointed as Director at Dogwood Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Alan Yu as a director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.